Item 5.07 Submission of Matters to a Vote of Security Holders.
(1) The stockholders elected AbbVie's Class III Directors with terms expiring in 2024, as follows: Name For Against Broker Non-Votes
(2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2021, as follows: For Against Abstain 1,443,141,768 38,474,335 2,332,381 (3) The stockholders approved, on an advisory basis, the compensation of AbbVie's named executive officers listed in the proxy statement for the 2021 annual meeting, as follows: For Against Abstain Broker Non-Votes 1,088,078,054 122,760,887 6,168,935 266,940,608 (4) The stockholders approved the Amended and Restated 2013 Incentive Stock Program, as follows: For Against Abstain Broker Non-Votes 1,151,977,015 60,300,643 4,730,218 266,940,608 (5) The stockholders approved the Amended and Restated 2013 Employee Stock Purchase Plan for Non-U.S. Employees, as follows: For Against Abstain Broker Non-Votes 1,179,691,622 33,184,479 4,131,775 266,940,608 (6) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows: For Against Abstain Broker Non-Votes 1,200,648,034 12,015,517 4,344,325 266,940,608 (7) The stockholders did not approve a stockholder proposal to issue a lobbying report, as follows: For Against Abstain Broker Non-Votes 435,784,510 770,846,870 10,376,496 266,940,608 (8) The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows: For Against Abstain Broker Non-Votes
330,233,388 831,267,134 55,507,354 266,940,608
© Edgar Online, source